Drugs / rSm-p80
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05762393 | Nov 2023 → May 2025 | schistosomiasis | International Vaccine Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rSm-p80 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05762393 ↗ |
| Modality | Vaccine | “Combination vaccine containing rSm-p80 antigen and GLA-SE adjuvant.” NCT05762393 ↗ |
| Route | Intramuscular | “given intramuscularly in healthy adults (20-59 years old).” NCT05762393 ↗ |